» Articles » PMID: 32883323

Variability and Change over Time of Weight and BMI Among Adolescents and Adults with Prader-Willi Syndrome: a 6-month Text-based Observational Study

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2020 Sep 5
PMID 32883323
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder in which hyperphagia (excessive appetite) is a hallmark feature. Understanding how weight changes over time in this population is important for capturing the contemporary natural history of the disorder as well as assessing the impact of new treatments for hyperphagia. Therefore, we aimed to determine the feasibility of a remote assessment of weight change over time in PWS.

Methods: We developed a text message-based, prospective cohort study of adolescents and adults with PWS to assess changes in weight and body mass index (BMI) over a six-month period. Weight was collected weekly, while changes in height, living situation, access to food, activity level, and medication were collected at three-month intervals.

Results: One hundred and sixty-five participants enrolled in the study, with a mean age of 19.7 years (range 12-48). There was considerable variability in weight across participants (range: 76.8-207.7 kg). Thirty-three percent of the participants were normal weight, while 15% were overweight and 52% were obese. Overall, the weight of the study participants increased over the study period (mean weight change + 2.35%), while BMI was relatively stable, albeit high (mean BMI of 31.4 at baseline, mean BMI percent change + 1.42%). Changes in living situation, activity, food access, and medication had limited impact on weight and BMI changes. Multivariable analysis found that time, sex, age, and percentage of life on growth hormone (GH) therapy were statistically significant fixed effects. Participants submitted more than 95% of possible weight data points across the 26 weeks of the study.

Conclusions: This remote, observational study of weight change in PWS showed small increases in weight and BMI over a six-month period. Participants were highly compliant with this text message-based study, suggesting that mobile technology-based data collection was manageable for the participants. We anticipate that the results of this study will inform clinical trials for hyperphagia/obesity related therapies in PWS and provide a basis for understanding the efficacy of new therapies for hyperphagia in the real-world setting.

Citing Articles

Composite variable bias: causal analysis of weight outcomes.

Ali R, Prestwich A, Ge J, Griffiths C, Allmendinger R, Shahgholian A Int J Obes (Lond). 2025; .

PMID: 40057559 DOI: 10.1038/s41366-025-01732-6.


Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study.

Lammer C, Backeljauw P, Tauber M, Kanumakala S, Loche S, Otfried Schwab K Ther Adv Endocrinol Metab. 2024; 15:20420188241264343.

PMID: 39371577 PMC: 11450727. DOI: 10.1177/20420188241264343.


Development of an International Database for a Rare Genetic Disorder: The Duplication Database (MDBase).

Ta D, Downs J, Baynam G, Wilson A, Richmond P, Schmidt A Children (Basel). 2022; 9(8).

PMID: 35892614 PMC: 9332564. DOI: 10.3390/children9081111.


Demographics and medical comorbidities among hospitalized patients with Prader-Willi Syndrome: A National Inpatient Sample analysis.

Luccarelli J Am J Med Genet A. 2022; 188(10):2899-2907.

PMID: 35838073 PMC: 9474715. DOI: 10.1002/ajmg.a.62901.

References
1.
Nordstrom M, Paus B, Andersen L, Kolset S . Dietary aspects related to health and obesity in Williams syndrome, Down syndrome, and Prader-Willi syndrome. Food Nutr Res. 2015; 59:25487. PMC: 4317472. DOI: 10.3402/fnr.v59.25487. View

2.
Salehi P, Hsu I, Azen C, Mittelman S, Geffner M, Jeandron D . Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes. 2016; 12(3):221-228. PMC: 5288290. DOI: 10.1111/ijpo.12131. View

3.
McCandless S, Yanovski J, Miller J, Fu C, Bird L, Salehi P . Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(12):1751-1761. PMC: 5673540. DOI: 10.1111/dom.13021. View

4.
Kimonis V, Tamura R, Gold J, Patel N, Surampalli A, Manazir J . Early Diagnosis in Prader-Willi Syndrome Reduces Obesity and Associated Co-Morbidities. Genes (Basel). 2019; 10(11). PMC: 6896038. DOI: 10.3390/genes10110898. View

5.
Dykens E, Roof E, Hunt-Hawkins H . Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J Child Psychol Psychiatry. 2016; 58(1):64-74. PMC: 5161611. DOI: 10.1111/jcpp.12601. View